Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
15.15 USD   +0.60%
12/02Deciphera Pharmaceuticals Inc. to Present at the JMP Securities Hematology and Oncology Summit
AQ
12/01Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
BU
11/09Deciphera Pharmaceuticals, Inc. to Participate in Upcoming November 2022 Investor Conferences
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating

09/12/2022 | 12:18pm EST


ę MT Newswires 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
12/02Deciphera Pharmaceuticals Inc. to Present at the JMP Securities Hematology and Oncology..
AQ
12/01Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncolog..
BU
11/09Deciphera Pharmaceuticals, Inc. to Participate in Upcoming November 2022 Investor Confe..
AQ
11/08Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
BU
11/03Transcript : Deciphera Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, ..
CI
11/03Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Reports Q3 Revenue $32.2M, vs. Street E..
MT
11/03Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Reports Q3 Loss $-0.55, vs. Street Est ..
MT
11/03DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
11/03Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
BU
11/03Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 132 M - -
Net income 2022 -179 M - -
Net cash 2022 89,3 M - -
P/E ratio 2022 -6,06x
Yield 2022 -
Capitalization 1 024 M 1 024 M -
EV / Sales 2022 7,06x
EV / Sales 2023 5,07x
Nbr of Employees 280
Free-Float 72,7%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 15,15 $
Average target price 19,61 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.54.15%1 018
VERTEX PHARMACEUTICALS41.99%80 039
REGENERON PHARMACEUTICALS, INC.18.36%79 831
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-33.48%32 589
GENMAB A/S23.38%29 957